nodes	percent_of_prediction	percent_of_DWPC	metapath
Bexarotene—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.141	0.343	CbGbCtD
Bexarotene—CYP2C9—Progesterone—uterine cancer	0.0937	0.227	CbGbCtD
Bexarotene—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0823	0.199	CbGbCtD
Bexarotene—CYP3A4—Progesterone—uterine cancer	0.0545	0.132	CbGbCtD
Bexarotene—CYP3A4—Etoposide—uterine cancer	0.0244	0.0591	CbGbCtD
Bexarotene—CYP3A4—Doxorubicin—uterine cancer	0.0166	0.0403	CbGbCtD
Bexarotene—RXRA—Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol—AKR1C3—uterine cancer	0.00257	0.0173	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptor transcription pathway—ESR2—uterine cancer	0.00246	0.0165	CbGpPWpGaD
Bexarotene—RXRA—Bile acid and bile salt metabolism—AKR1C1—uterine cancer	0.00242	0.0162	CbGpPWpGaD
Bexarotene—RXRA—Synthesis of bile acids and bile salts—AKR1C3—uterine cancer	0.00234	0.0157	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptor transcription pathway—ESR2—uterine cancer	0.00232	0.0155	CbGpPWpGaD
Bexarotene—RXRA—Endogenous sterols—CYP19A1—uterine cancer	0.00207	0.0139	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptors—ESR1—uterine cancer	0.00189	0.0127	CbGpPWpGaD
Bexarotene—RXRA—Bile acid and bile salt metabolism—AKR1C3—uterine cancer	0.00186	0.0125	CbGpPWpGaD
Bexarotene—CYP3A4—Benzo(a)pyrene metabolism—AKR1C1—uterine cancer	0.0018	0.0121	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptors—ESR1—uterine cancer	0.00178	0.0119	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptors—PGR—uterine cancer	0.00174	0.0116	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—MET—uterine cancer	0.00166	0.0111	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—MET—uterine cancer	0.00156	0.0105	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptors—ESR2—uterine cancer	0.00153	0.0103	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptor transcription pathway—ESR1—uterine cancer	0.00149	0.01	CbGpPWpGaD
Bexarotene—RXRA—The citric acid (TCA) cycle and respiratory electron transport—NDUFB11—uterine cancer	0.00148	0.00991	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—YWHAE—uterine cancer	0.00145	0.0097	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—CDH1—uterine cancer	0.00144	0.00964	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptor transcription pathway—ESR1—uterine cancer	0.0014	0.00943	CbGpPWpGaD
Bexarotene—CYP3A4—Benzo(a)pyrene metabolism—AKR1C3—uterine cancer	0.00139	0.00931	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptor transcription pathway—PGR—uterine cancer	0.00137	0.0092	CbGpPWpGaD
Bexarotene—RXRG—Retinoic acid receptors-mediated signaling—EP300—uterine cancer	0.00136	0.00915	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—CDH1—uterine cancer	0.00135	0.00907	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—HMGA1—uterine cancer	0.00132	0.00888	CbGpPWpGaD
Bexarotene—RXRA—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.00131	0.00878	CbGpPWpGaD
Bexarotene—RXRB—Retinoic acid receptors-mediated signaling—EP300—uterine cancer	0.00128	0.0086	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—MAP3K4—uterine cancer	0.00126	0.00848	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—ERBB2—uterine cancer	0.00121	0.00814	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptor transcription pathway—ESR2—uterine cancer	0.00121	0.0081	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—ERBB2—uterine cancer	0.00114	0.00765	CbGpPWpGaD
Bexarotene—RXRA—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.00106	0.00712	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—SOCS3—uterine cancer	0.000991	0.00665	CbGpPWpGaD
Bexarotene—RXRA—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000963	0.00646	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptors—ESR1—uterine cancer	0.000927	0.00622	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—SMAD3—uterine cancer	0.000866	0.00581	CbGpPWpGaD
Bexarotene—RXRG—Regulation of Androgen receptor activity—EP300—uterine cancer	0.000865	0.0058	CbGpPWpGaD
Bexarotene—RXRG—Retinoic acid receptors-mediated signaling—AKT1—uterine cancer	0.000824	0.00553	CbGpPWpGaD
Bexarotene—RXRB—Regulation of Androgen receptor activity—EP300—uterine cancer	0.000813	0.00546	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—MET—uterine cancer	0.000813	0.00545	CbGpPWpGaD
Bexarotene—RXRA—REV-ERBA represses gene expression—EP300—uterine cancer	0.000799	0.00536	CbGpPWpGaD
Bexarotene—RXRA—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.00078	0.00524	CbGpPWpGaD
Bexarotene—RXRB—Retinoic acid receptors-mediated signaling—AKT1—uterine cancer	0.000775	0.0052	CbGpPWpGaD
Bexarotene—RXRA—RORA activates circadian gene expression—EP300—uterine cancer	0.000773	0.00519	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptor transcription pathway—ESR1—uterine cancer	0.000732	0.00491	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—PIK3CA—uterine cancer	0.000729	0.00489	CbGpPWpGaD
Bexarotene—RXRA—NRF2 pathway—NFE2L2—uterine cancer	0.000725	0.00487	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	0.000706	0.00474	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—CDH1—uterine cancer	0.000704	0.00472	CbGpPWpGaD
Bexarotene—RXRA—NRF2 pathway—GPX3—uterine cancer	0.000692	0.00464	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—PIK3CA—uterine cancer	0.000686	0.0046	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—HRAS—uterine cancer	0.000675	0.00453	CbGpPWpGaD
Bexarotene—RXRA—Retinoic acid receptors-mediated signaling—EP300—uterine cancer	0.000668	0.00448	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—PHF1—uterine cancer	0.000656	0.0044	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—HMGA1—uterine cancer	0.000649	0.00435	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—HRAS—uterine cancer	0.000634	0.00426	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—PLXNA3—uterine cancer	0.000628	0.00422	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—PHF1—uterine cancer	0.000617	0.00414	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—AKT1—uterine cancer	0.000596	0.004	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—ERBB2—uterine cancer	0.000594	0.00399	CbGpPWpGaD
Bexarotene—RXRA—BMAL1:CLOCK,NPAS2 activates circadian gene expression—EP300—uterine cancer	0.000565	0.00379	CbGpPWpGaD
Bexarotene—RXRA—Biological oxidations—CYP11A1—uterine cancer	0.000563	0.00378	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—AKT1—uterine cancer	0.00056	0.00376	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—CHD4—uterine cancer	0.000558	0.00374	CbGpPWpGaD
Bexarotene—CYP2C9—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.000534	0.00358	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—CHD4—uterine cancer	0.000524	0.00352	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.0005	0.00336	CbGpPWpGaD
Bexarotene—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000488	0.00328	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—SOCS3—uterine cancer	0.000486	0.00326	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—PGR—uterine cancer	0.000483	0.00324	CbGpPWpGaD
Bexarotene—CYP2C9—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000482	0.00323	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—SUZ12—uterine cancer	0.000467	0.00314	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—PGR—uterine cancer	0.000455	0.00305	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—CTNNB1—uterine cancer	0.000454	0.00305	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	0.000453	0.00304	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—SUZ12—uterine cancer	0.000439	0.00295	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—ESR2—uterine cancer	0.000426	0.00286	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—SMAD3—uterine cancer	0.000424	0.00285	CbGpPWpGaD
Bexarotene—RXRA—Regulation of Androgen receptor activity—EP300—uterine cancer	0.000424	0.00284	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	0.00042	0.00282	CbGpPWpGaD
Bexarotene—RXRA—Biological oxidations—CYP19A1—uterine cancer	0.000415	0.00278	CbGpPWpGaD
Bexarotene—RXRA—Circadian Clock—EP300—uterine cancer	0.000411	0.00276	CbGpPWpGaD
Bexarotene—RXRA—Retinoic acid receptors-mediated signaling—AKT1—uterine cancer	0.000404	0.00271	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—ESR2—uterine cancer	0.0004	0.00269	CbGpPWpGaD
Bexarotene—CYP2C9—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000396	0.00266	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	0.000381	0.00256	CbGpPWpGaD
Bexarotene—CYP2C9—Metapathway biotransformation—AKR1B10—uterine cancer	0.000373	0.0025	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.000362	0.00243	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.000362	0.00243	CbGpPWpGaD
Bexarotene—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000359	0.00241	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—PIK3CA—uterine cancer	0.000357	0.0024	CbGpPWpGaD
Bexarotene—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000355	0.00238	CbGpPWpGaD
Bexarotene—CYP2C9—Metapathway biotransformation—AKR1B1—uterine cancer	0.000347	0.00233	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—CDKN2B—uterine cancer	0.000346	0.00232	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.000344	0.00231	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	0.000342	0.00229	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—HRAS—uterine cancer	0.000331	0.00222	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—HNF1B—uterine cancer	0.00033	0.00221	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—CDKN2B—uterine cancer	0.000326	0.00219	CbGpPWpGaD
Bexarotene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000322	0.00216	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—PHF1—uterine cancer	0.000321	0.00216	CbGpPWpGaD
Bexarotene—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000318	0.00213	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—SMAD3—uterine cancer	0.000316	0.00212	CbGpPWpGaD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—EP300—uterine cancer	0.000314	0.00211	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—SMAD3—uterine cancer	0.000297	0.002	CbGpPWpGaD
Bexarotene—CYP3A4—Tryptophan metabolism—CYP19A1—uterine cancer	0.000293	0.00197	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—AKT1—uterine cancer	0.000292	0.00196	CbGpPWpGaD
Bexarotene—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000291	0.00196	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—CHD4—uterine cancer	0.000273	0.00183	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.000265	0.00178	CbGpPWpGaD
Bexarotene—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000261	0.00175	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—ESR1—uterine cancer	0.000258	0.00173	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	0.000255	0.00171	CbGpPWpGaD
Bexarotene—CYP2C9—Metapathway biotransformation—AKR1C1—uterine cancer	0.000254	0.00171	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	0.000246	0.00165	CbGpPWpGaD
Bexarotene—Confusional state—Etoposide—uterine cancer	0.000244	0.000557	CcSEcCtD
Bexarotene—Muscular weakness—Epirubicin—uterine cancer	0.000243	0.000555	CcSEcCtD
Bexarotene—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.000243	0.000555	CcSEcCtD
Bexarotene—RXRB—Generic Transcription Pathway—ESR1—uterine cancer	0.000243	0.00163	CbGpPWpGaD
Bexarotene—Mood swings—Doxorubicin—uterine cancer	0.000242	0.000552	CcSEcCtD
Bexarotene—Infection—Etoposide—uterine cancer	0.00024	0.000549	CcSEcCtD
Bexarotene—Abdominal distension—Epirubicin—uterine cancer	0.00024	0.000548	CcSEcCtD
Bexarotene—Ataxia—Doxorubicin—uterine cancer	0.00024	0.000548	CcSEcCtD
Bexarotene—Asthenia—Dactinomycin—uterine cancer	0.00024	0.000547	CcSEcCtD
Bexarotene—Blood creatinine increased—Doxorubicin—uterine cancer	0.000239	0.000546	CcSEcCtD
Bexarotene—Influenza—Epirubicin—uterine cancer	0.000238	0.000544	CcSEcCtD
Bexarotene—Dysphagia—Epirubicin—uterine cancer	0.000238	0.000544	CcSEcCtD
Bexarotene—Dehydration—Doxorubicin—uterine cancer	0.000237	0.000542	CcSEcCtD
Bexarotene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000237	0.00159	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—PGR—uterine cancer	0.000237	0.00159	CbGpPWpGaD
Bexarotene—Thrombocytopenia—Etoposide—uterine cancer	0.000237	0.000541	CcSEcCtD
Bexarotene—RXRA—PPARA activates gene expression—EP300—uterine cancer	0.000236	0.00159	CbGpPWpGaD
Bexarotene—Tachycardia—Etoposide—uterine cancer	0.000236	0.000539	CcSEcCtD
Bexarotene—Eosinophilia—Epirubicin—uterine cancer	0.000236	0.000539	CcSEcCtD
Bexarotene—Liver function test abnormal—Doxorubicin—uterine cancer	0.000236	0.000538	CcSEcCtD
Bexarotene—Skin disorder—Etoposide—uterine cancer	0.000235	0.000536	CcSEcCtD
Bexarotene—Dry skin—Doxorubicin—uterine cancer	0.000234	0.000534	CcSEcCtD
Bexarotene—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000234	0.00157	CbGpPWpGaD
Bexarotene—Hyperhidrosis—Etoposide—uterine cancer	0.000234	0.000534	CcSEcCtD
Bexarotene—Pancreatitis—Epirubicin—uterine cancer	0.000234	0.000534	CcSEcCtD
Bexarotene—RXRG—Gene Expression—PGR—uterine cancer	0.000233	0.00156	CbGpPWpGaD
Bexarotene—Hypokalaemia—Doxorubicin—uterine cancer	0.000232	0.00053	CcSEcCtD
Bexarotene—Angina pectoris—Epirubicin—uterine cancer	0.000232	0.00053	CcSEcCtD
Bexarotene—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—uterine cancer	0.000231	0.00155	CbGpPWpGaD
Bexarotene—Anorexia—Etoposide—uterine cancer	0.000231	0.000526	CcSEcCtD
Bexarotene—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.00023	0.000525	CcSEcCtD
Bexarotene—Bronchitis—Epirubicin—uterine cancer	0.000229	0.000523	CcSEcCtD
Bexarotene—RXRA—Gene Expression—SUZ12—uterine cancer	0.000229	0.00154	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	0.000229	0.00153	CbGpPWpGaD
Bexarotene—Diarrhoea—Dactinomycin—uterine cancer	0.000229	0.000522	CcSEcCtD
Bexarotene—Pancytopenia—Epirubicin—uterine cancer	0.000226	0.000517	CcSEcCtD
Bexarotene—Muscular weakness—Doxorubicin—uterine cancer	0.000225	0.000514	CcSEcCtD
Bexarotene—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000225	0.000514	CcSEcCtD
Bexarotene—CYP2C9—Metapathway biotransformation—GPX3—uterine cancer	0.000223	0.0015	CbGpPWpGaD
Bexarotene—Dysuria—Epirubicin—uterine cancer	0.000223	0.000509	CcSEcCtD
Bexarotene—Neutropenia—Epirubicin—uterine cancer	0.000223	0.000509	CcSEcCtD
Bexarotene—RXRA—Metabolism—SRD5A2—uterine cancer	0.000223	0.00149	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—NDUFB11—uterine cancer	0.000223	0.00149	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—CTNNB1—uterine cancer	0.000222	0.00149	CbGpPWpGaD
Bexarotene—Abdominal distension—Doxorubicin—uterine cancer	0.000222	0.000507	CcSEcCtD
Bexarotene—RXRG—Gene Expression—EZH2—uterine cancer	0.000221	0.00148	CbGpPWpGaD
Bexarotene—Influenza—Doxorubicin—uterine cancer	0.000221	0.000504	CcSEcCtD
Bexarotene—Dysphagia—Doxorubicin—uterine cancer	0.000221	0.000504	CcSEcCtD
Bexarotene—Pollakiuria—Epirubicin—uterine cancer	0.00022	0.000503	CcSEcCtD
Bexarotene—RXRB—Gene Expression—PGR—uterine cancer	0.000219	0.00147	CbGpPWpGaD
Bexarotene—Eosinophilia—Doxorubicin—uterine cancer	0.000218	0.000499	CcSEcCtD
Bexarotene—Photosensitivity reaction—Epirubicin—uterine cancer	0.000218	0.000497	CcSEcCtD
Bexarotene—Paraesthesia—Etoposide—uterine cancer	0.000217	0.000496	CcSEcCtD
Bexarotene—Weight increased—Epirubicin—uterine cancer	0.000217	0.000495	CcSEcCtD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	0.000216	0.00145	CbGpPWpGaD
Bexarotene—Pancreatitis—Doxorubicin—uterine cancer	0.000216	0.000494	CcSEcCtD
Bexarotene—Weight decreased—Epirubicin—uterine cancer	0.000216	0.000492	CcSEcCtD
Bexarotene—Dyspnoea—Etoposide—uterine cancer	0.000216	0.000492	CcSEcCtD
Bexarotene—Hyperglycaemia—Epirubicin—uterine cancer	0.000215	0.000491	CcSEcCtD
Bexarotene—Somnolence—Etoposide—uterine cancer	0.000215	0.000491	CcSEcCtD
Bexarotene—Angina pectoris—Doxorubicin—uterine cancer	0.000215	0.000491	CcSEcCtD
Bexarotene—Pneumonia—Epirubicin—uterine cancer	0.000214	0.000488	CcSEcCtD
Bexarotene—Vomiting—Dactinomycin—uterine cancer	0.000212	0.000485	CcSEcCtD
Bexarotene—Bronchitis—Doxorubicin—uterine cancer	0.000212	0.000484	CcSEcCtD
Bexarotene—Rash—Dactinomycin—uterine cancer	0.000211	0.000481	CcSEcCtD
Bexarotene—CYP2C9—Biological oxidations—CYP11A1—uterine cancer	0.00021	0.00141	CbGpPWpGaD
Bexarotene—Decreased appetite—Etoposide—uterine cancer	0.00021	0.00048	CcSEcCtD
Bexarotene—Pancytopenia—Doxorubicin—uterine cancer	0.00021	0.000478	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Etoposide—uterine cancer	0.000209	0.000477	CcSEcCtD
Bexarotene—RXRA—Generic Transcription Pathway—ESR2—uterine cancer	0.000209	0.0014	CbGpPWpGaD
Bexarotene—Fatigue—Etoposide—uterine cancer	0.000209	0.000476	CcSEcCtD
Bexarotene—Neuropathy peripheral—Epirubicin—uterine cancer	0.000208	0.000476	CcSEcCtD
Bexarotene—RXRB—Gene Expression—EZH2—uterine cancer	0.000208	0.00139	CbGpPWpGaD
Bexarotene—CYP2C9—Metapathway biotransformation—CYP11A1—uterine cancer	0.000207	0.00139	CbGpPWpGaD
Bexarotene—Stomatitis—Epirubicin—uterine cancer	0.000207	0.000473	CcSEcCtD
Bexarotene—Jaundice—Epirubicin—uterine cancer	0.000207	0.000473	CcSEcCtD
Bexarotene—Pain—Etoposide—uterine cancer	0.000207	0.000472	CcSEcCtD
Bexarotene—Constipation—Etoposide—uterine cancer	0.000207	0.000472	CcSEcCtD
Bexarotene—Urinary tract infection—Epirubicin—uterine cancer	0.000207	0.000472	CcSEcCtD
Bexarotene—Conjunctivitis—Epirubicin—uterine cancer	0.000207	0.000472	CcSEcCtD
Bexarotene—Dysuria—Doxorubicin—uterine cancer	0.000206	0.000471	CcSEcCtD
Bexarotene—Neutropenia—Doxorubicin—uterine cancer	0.000206	0.000471	CcSEcCtD
Bexarotene—RXRG—Gene Expression—ESR2—uterine cancer	0.000205	0.00138	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	0.000204	0.00137	CbGpPWpGaD
Bexarotene—Sweating—Epirubicin—uterine cancer	0.000204	0.000465	CcSEcCtD
Bexarotene—Pollakiuria—Doxorubicin—uterine cancer	0.000204	0.000465	CcSEcCtD
Bexarotene—Haematuria—Epirubicin—uterine cancer	0.000203	0.000463	CcSEcCtD
Bexarotene—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000201	0.00046	CcSEcCtD
Bexarotene—Weight increased—Doxorubicin—uterine cancer	0.000201	0.000458	CcSEcCtD
Bexarotene—Epistaxis—Epirubicin—uterine cancer	0.000201	0.000458	CcSEcCtD
Bexarotene—Weight decreased—Doxorubicin—uterine cancer	0.0002	0.000456	CcSEcCtD
Bexarotene—Sinusitis—Epirubicin—uterine cancer	0.000199	0.000455	CcSEcCtD
Bexarotene—Feeling abnormal—Etoposide—uterine cancer	0.000199	0.000455	CcSEcCtD
Bexarotene—Hyperglycaemia—Doxorubicin—uterine cancer	0.000199	0.000454	CcSEcCtD
Bexarotene—Nausea—Dactinomycin—uterine cancer	0.000199	0.000453	CcSEcCtD
Bexarotene—Pneumonia—Doxorubicin—uterine cancer	0.000198	0.000452	CcSEcCtD
Bexarotene—Gastrointestinal pain—Etoposide—uterine cancer	0.000198	0.000452	CcSEcCtD
Bexarotene—CYP2C9—Metapathway biotransformation—AKR1C3—uterine cancer	0.000196	0.00131	CbGpPWpGaD
Bexarotene—Neuropathy peripheral—Doxorubicin—uterine cancer	0.000193	0.00044	CcSEcCtD
Bexarotene—RXRB—Gene Expression—ESR2—uterine cancer	0.000193	0.00129	CbGpPWpGaD
Bexarotene—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000192	0.00129	CbGpPWpGaD
Bexarotene—Haemoglobin—Epirubicin—uterine cancer	0.000192	0.000438	CcSEcCtD
Bexarotene—Jaundice—Doxorubicin—uterine cancer	0.000192	0.000438	CcSEcCtD
Bexarotene—Stomatitis—Doxorubicin—uterine cancer	0.000192	0.000438	CcSEcCtD
Bexarotene—Rhinitis—Epirubicin—uterine cancer	0.000191	0.000437	CcSEcCtD
Bexarotene—Abdominal pain—Etoposide—uterine cancer	0.000191	0.000437	CcSEcCtD
Bexarotene—Body temperature increased—Etoposide—uterine cancer	0.000191	0.000437	CcSEcCtD
Bexarotene—Urinary tract infection—Doxorubicin—uterine cancer	0.000191	0.000436	CcSEcCtD
Bexarotene—Conjunctivitis—Doxorubicin—uterine cancer	0.000191	0.000436	CcSEcCtD
Bexarotene—Haemorrhage—Epirubicin—uterine cancer	0.000191	0.000436	CcSEcCtD
Bexarotene—Hypoaesthesia—Epirubicin—uterine cancer	0.00019	0.000433	CcSEcCtD
Bexarotene—Pharyngitis—Epirubicin—uterine cancer	0.000189	0.000432	CcSEcCtD
Bexarotene—Sweating—Doxorubicin—uterine cancer	0.000189	0.000431	CcSEcCtD
Bexarotene—Urinary tract disorder—Epirubicin—uterine cancer	0.000188	0.00043	CcSEcCtD
Bexarotene—Oedema peripheral—Epirubicin—uterine cancer	0.000188	0.000429	CcSEcCtD
Bexarotene—Haematuria—Doxorubicin—uterine cancer	0.000188	0.000428	CcSEcCtD
Bexarotene—Connective tissue disorder—Epirubicin—uterine cancer	0.000188	0.000428	CcSEcCtD
Bexarotene—Urethral disorder—Epirubicin—uterine cancer	0.000187	0.000427	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	0.000187	0.00125	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000187	0.00125	CbGpPWpGaD
Bexarotene—Epistaxis—Doxorubicin—uterine cancer	0.000186	0.000424	CcSEcCtD
Bexarotene—Sinusitis—Doxorubicin—uterine cancer	0.000185	0.000421	CcSEcCtD
Bexarotene—Eye disorder—Epirubicin—uterine cancer	0.000178	0.000407	CcSEcCtD
Bexarotene—Hypersensitivity—Etoposide—uterine cancer	0.000178	0.000407	CcSEcCtD
Bexarotene—Tinnitus—Epirubicin—uterine cancer	0.000178	0.000406	CcSEcCtD
Bexarotene—Haemoglobin—Doxorubicin—uterine cancer	0.000177	0.000405	CcSEcCtD
Bexarotene—Cardiac disorder—Epirubicin—uterine cancer	0.000177	0.000404	CcSEcCtD
Bexarotene—Rhinitis—Doxorubicin—uterine cancer	0.000177	0.000404	CcSEcCtD
Bexarotene—Haemorrhage—Doxorubicin—uterine cancer	0.000177	0.000403	CcSEcCtD
Bexarotene—Hypoaesthesia—Doxorubicin—uterine cancer	0.000176	0.000401	CcSEcCtD
Bexarotene—Pharyngitis—Doxorubicin—uterine cancer	0.000175	0.0004	CcSEcCtD
Bexarotene—Urinary tract disorder—Doxorubicin—uterine cancer	0.000174	0.000398	CcSEcCtD
Bexarotene—Oedema peripheral—Doxorubicin—uterine cancer	0.000174	0.000397	CcSEcCtD
Bexarotene—Asthenia—Etoposide—uterine cancer	0.000174	0.000396	CcSEcCtD
Bexarotene—Connective tissue disorder—Doxorubicin—uterine cancer	0.000174	0.000396	CcSEcCtD
Bexarotene—Angiopathy—Epirubicin—uterine cancer	0.000173	0.000395	CcSEcCtD
Bexarotene—Urethral disorder—Doxorubicin—uterine cancer	0.000173	0.000395	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	0.000173	0.00116	CbGpPWpGaD
Bexarotene—Chills—Epirubicin—uterine cancer	0.000171	0.000391	CcSEcCtD
Bexarotene—Pruritus—Etoposide—uterine cancer	0.000171	0.000391	CcSEcCtD
Bexarotene—Arrhythmia—Epirubicin—uterine cancer	0.00017	0.000389	CcSEcCtD
Bexarotene—RXRA—Generic Transcription Pathway—CDKN2B—uterine cancer	0.00017	0.00114	CbGpPWpGaD
Bexarotene—Alopecia—Epirubicin—uterine cancer	0.000169	0.000385	CcSEcCtD
Bexarotene—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	0.000168	0.00113	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—CDKN2B—uterine cancer	0.000167	0.00112	CbGpPWpGaD
Bexarotene—Erythema—Epirubicin—uterine cancer	0.000166	0.000379	CcSEcCtD
Bexarotene—Malnutrition—Epirubicin—uterine cancer	0.000166	0.000379	CcSEcCtD
Bexarotene—Diarrhoea—Etoposide—uterine cancer	0.000165	0.000378	CcSEcCtD
Bexarotene—Eye disorder—Doxorubicin—uterine cancer	0.000165	0.000377	CcSEcCtD
Bexarotene—Tinnitus—Doxorubicin—uterine cancer	0.000165	0.000376	CcSEcCtD
Bexarotene—Cardiac disorder—Doxorubicin—uterine cancer	0.000164	0.000374	CcSEcCtD
Bexarotene—Flatulence—Epirubicin—uterine cancer	0.000164	0.000374	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	0.000164	0.0011	CbGpPWpGaD
Bexarotene—Tension—Epirubicin—uterine cancer	0.000163	0.000372	CcSEcCtD
Bexarotene—Dysgeusia—Epirubicin—uterine cancer	0.000163	0.000371	CcSEcCtD
Bexarotene—Nervousness—Epirubicin—uterine cancer	0.000161	0.000368	CcSEcCtD
Bexarotene—RXRA—Metabolism—STAR—uterine cancer	0.000161	0.00108	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—AKR1B1—uterine cancer	0.000161	0.00108	CbGpPWpGaD
Bexarotene—Back pain—Epirubicin—uterine cancer	0.000161	0.000367	CcSEcCtD
Bexarotene—Angiopathy—Doxorubicin—uterine cancer	0.00016	0.000366	CcSEcCtD
Bexarotene—Dizziness—Etoposide—uterine cancer	0.00016	0.000365	CcSEcCtD
Bexarotene—Muscle spasms—Epirubicin—uterine cancer	0.00016	0.000365	CcSEcCtD
Bexarotene—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—uterine cancer	0.000159	0.00107	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	0.000159	0.00107	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	0.000159	0.00107	CbGpPWpGaD
Bexarotene—Chills—Doxorubicin—uterine cancer	0.000158	0.000362	CcSEcCtD
Bexarotene—Arrhythmia—Doxorubicin—uterine cancer	0.000158	0.00036	CcSEcCtD
Bexarotene—RXRB—Gene Expression—CDKN2B—uterine cancer	0.000157	0.00105	CbGpPWpGaD
Bexarotene—Alopecia—Doxorubicin—uterine cancer	0.000156	0.000356	CcSEcCtD
Bexarotene—RXRA—Generic Transcription Pathway—SMAD3—uterine cancer	0.000155	0.00104	CbGpPWpGaD
Bexarotene—CYP2C9—Biological oxidations—CYP19A1—uterine cancer	0.000155	0.00104	CbGpPWpGaD
Bexarotene—Ill-defined disorder—Epirubicin—uterine cancer	0.000154	0.000352	CcSEcCtD
Bexarotene—Vomiting—Etoposide—uterine cancer	0.000154	0.000351	CcSEcCtD
Bexarotene—Malnutrition—Doxorubicin—uterine cancer	0.000154	0.000351	CcSEcCtD
Bexarotene—Erythema—Doxorubicin—uterine cancer	0.000154	0.000351	CcSEcCtD
Bexarotene—Anaemia—Epirubicin—uterine cancer	0.000154	0.000351	CcSEcCtD
Bexarotene—Agitation—Epirubicin—uterine cancer	0.000153	0.000349	CcSEcCtD
Bexarotene—CYP2C9—Metapathway biotransformation—CYP19A1—uterine cancer	0.000153	0.00102	CbGpPWpGaD
Bexarotene—Rash—Etoposide—uterine cancer	0.000153	0.000348	CcSEcCtD
Bexarotene—Dermatitis—Etoposide—uterine cancer	0.000152	0.000348	CcSEcCtD
Bexarotene—RXRG—Gene Expression—SMAD3—uterine cancer	0.000152	0.00102	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	0.000152	0.00102	CbGpPWpGaD
Bexarotene—Headache—Etoposide—uterine cancer	0.000152	0.000346	CcSEcCtD
Bexarotene—Flatulence—Doxorubicin—uterine cancer	0.000151	0.000346	CcSEcCtD
Bexarotene—Tension—Doxorubicin—uterine cancer	0.000151	0.000344	CcSEcCtD
Bexarotene—Dysgeusia—Doxorubicin—uterine cancer	0.000151	0.000344	CcSEcCtD
Bexarotene—Malaise—Epirubicin—uterine cancer	0.00015	0.000342	CcSEcCtD
Bexarotene—Nervousness—Doxorubicin—uterine cancer	0.000149	0.000341	CcSEcCtD
Bexarotene—Vertigo—Epirubicin—uterine cancer	0.000149	0.000341	CcSEcCtD
Bexarotene—Syncope—Epirubicin—uterine cancer	0.000149	0.00034	CcSEcCtD
Bexarotene—Leukopenia—Epirubicin—uterine cancer	0.000149	0.000339	CcSEcCtD
Bexarotene—Back pain—Doxorubicin—uterine cancer	0.000149	0.000339	CcSEcCtD
Bexarotene—Muscle spasms—Doxorubicin—uterine cancer	0.000148	0.000337	CcSEcCtD
Bexarotene—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	0.000147	0.000989	CbGpPWpGaD
Bexarotene—Palpitations—Epirubicin—uterine cancer	0.000147	0.000335	CcSEcCtD
Bexarotene—Loss of consciousness—Epirubicin—uterine cancer	0.000146	0.000333	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—SMAD3—uterine cancer	0.000146	0.000979	CbGpPWpGaD
Bexarotene—Cough—Epirubicin—uterine cancer	0.000145	0.000331	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	0.000144	0.000966	CbGpPWpGaD
Bexarotene—Nausea—Etoposide—uterine cancer	0.000144	0.000328	CcSEcCtD
Bexarotene—Hypertension—Epirubicin—uterine cancer	0.000143	0.000327	CcSEcCtD
Bexarotene—RXRB—Gene Expression—SMAD3—uterine cancer	0.000143	0.000961	CbGpPWpGaD
Bexarotene—Ill-defined disorder—Doxorubicin—uterine cancer	0.000143	0.000326	CcSEcCtD
Bexarotene—Anaemia—Doxorubicin—uterine cancer	0.000142	0.000324	CcSEcCtD
Bexarotene—Arthralgia—Epirubicin—uterine cancer	0.000141	0.000323	CcSEcCtD
Bexarotene—Myalgia—Epirubicin—uterine cancer	0.000141	0.000323	CcSEcCtD
Bexarotene—Chest pain—Epirubicin—uterine cancer	0.000141	0.000323	CcSEcCtD
Bexarotene—Agitation—Doxorubicin—uterine cancer	0.000141	0.000322	CcSEcCtD
Bexarotene—Anxiety—Epirubicin—uterine cancer	0.000141	0.000322	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.00014	0.000321	CcSEcCtD
Bexarotene—Discomfort—Epirubicin—uterine cancer	0.00014	0.000319	CcSEcCtD
Bexarotene—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	0.000139	0.000931	CbGpPWpGaD
Bexarotene—Malaise—Doxorubicin—uterine cancer	0.000139	0.000316	CcSEcCtD
Bexarotene—Dry mouth—Epirubicin—uterine cancer	0.000138	0.000316	CcSEcCtD
Bexarotene—Vertigo—Doxorubicin—uterine cancer	0.000138	0.000315	CcSEcCtD
Bexarotene—Syncope—Doxorubicin—uterine cancer	0.000138	0.000315	CcSEcCtD
Bexarotene—Leukopenia—Doxorubicin—uterine cancer	0.000138	0.000314	CcSEcCtD
Bexarotene—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	0.000137	0.000918	CbGpPWpGaD
Bexarotene—Confusional state—Epirubicin—uterine cancer	0.000137	0.000312	CcSEcCtD
Bexarotene—Palpitations—Doxorubicin—uterine cancer	0.000136	0.00031	CcSEcCtD
Bexarotene—Oedema—Epirubicin—uterine cancer	0.000136	0.00031	CcSEcCtD
Bexarotene—Loss of consciousness—Doxorubicin—uterine cancer	0.000135	0.000308	CcSEcCtD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.000135	0.000906	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.000135	0.000906	CbGpPWpGaD
Bexarotene—Infection—Epirubicin—uterine cancer	0.000135	0.000308	CcSEcCtD
Bexarotene—Cough—Doxorubicin—uterine cancer	0.000134	0.000306	CcSEcCtD
Bexarotene—Shock—Epirubicin—uterine cancer	0.000133	0.000305	CcSEcCtD
Bexarotene—Nervous system disorder—Epirubicin—uterine cancer	0.000133	0.000304	CcSEcCtD
Bexarotene—Thrombocytopenia—Epirubicin—uterine cancer	0.000133	0.000303	CcSEcCtD
Bexarotene—Hypertension—Doxorubicin—uterine cancer	0.000133	0.000303	CcSEcCtD
Bexarotene—Tachycardia—Epirubicin—uterine cancer	0.000132	0.000302	CcSEcCtD
Bexarotene—Skin disorder—Epirubicin—uterine cancer	0.000132	0.000301	CcSEcCtD
Bexarotene—Hyperhidrosis—Epirubicin—uterine cancer	0.000131	0.000299	CcSEcCtD
Bexarotene—Chest pain—Doxorubicin—uterine cancer	0.000131	0.000299	CcSEcCtD
Bexarotene—Arthralgia—Doxorubicin—uterine cancer	0.000131	0.000299	CcSEcCtD
Bexarotene—Myalgia—Doxorubicin—uterine cancer	0.000131	0.000299	CcSEcCtD
Bexarotene—Anxiety—Doxorubicin—uterine cancer	0.00013	0.000298	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.00013	0.000297	CcSEcCtD
Bexarotene—Discomfort—Doxorubicin—uterine cancer	0.000129	0.000295	CcSEcCtD
Bexarotene—Anorexia—Epirubicin—uterine cancer	0.000129	0.000295	CcSEcCtD
Bexarotene—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	0.000129	0.000867	CbGpPWpGaD
Bexarotene—Dry mouth—Doxorubicin—uterine cancer	0.000128	0.000292	CcSEcCtD
Bexarotene—Confusional state—Doxorubicin—uterine cancer	0.000126	0.000289	CcSEcCtD
Bexarotene—RXRA—Generic Transcription Pathway—ESR1—uterine cancer	0.000126	0.000849	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—POLD1—uterine cancer	0.000126	0.000848	CbGpPWpGaD
Bexarotene—Oedema—Doxorubicin—uterine cancer	0.000125	0.000286	CcSEcCtD
Bexarotene—Infection—Doxorubicin—uterine cancer	0.000125	0.000285	CcSEcCtD
Bexarotene—RXRG—Gene Expression—ESR1—uterine cancer	0.000124	0.000834	CbGpPWpGaD
Bexarotene—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000124	0.000282	CcSEcCtD
Bexarotene—Shock—Doxorubicin—uterine cancer	0.000123	0.000282	CcSEcCtD
Bexarotene—Nervous system disorder—Doxorubicin—uterine cancer	0.000123	0.000281	CcSEcCtD
Bexarotene—Thrombocytopenia—Doxorubicin—uterine cancer	0.000123	0.00028	CcSEcCtD
Bexarotene—Insomnia—Epirubicin—uterine cancer	0.000123	0.00028	CcSEcCtD
Bexarotene—Tachycardia—Doxorubicin—uterine cancer	0.000122	0.00028	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	0.000122	0.000821	CbGpPWpGaD
Bexarotene—Skin disorder—Doxorubicin—uterine cancer	0.000122	0.000278	CcSEcCtD
Bexarotene—Paraesthesia—Epirubicin—uterine cancer	0.000122	0.000278	CcSEcCtD
Bexarotene—Hyperhidrosis—Doxorubicin—uterine cancer	0.000121	0.000277	CcSEcCtD
Bexarotene—Dyspnoea—Epirubicin—uterine cancer	0.000121	0.000276	CcSEcCtD
Bexarotene—Somnolence—Epirubicin—uterine cancer	0.000121	0.000275	CcSEcCtD
Bexarotene—Anorexia—Doxorubicin—uterine cancer	0.00012	0.000273	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—MET—uterine cancer	0.00012	0.000802	CbGpPWpGaD
Bexarotene—Dyspepsia—Epirubicin—uterine cancer	0.000119	0.000272	CcSEcCtD
Bexarotene—RXRA—Metabolism—AKR1C1—uterine cancer	0.000118	0.000793	CbGpPWpGaD
Bexarotene—Decreased appetite—Epirubicin—uterine cancer	0.000118	0.000269	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000117	0.000267	CcSEcCtD
Bexarotene—Fatigue—Epirubicin—uterine cancer	0.000117	0.000267	CcSEcCtD
Bexarotene—RXRB—Gene Expression—ESR1—uterine cancer	0.000117	0.000784	CbGpPWpGaD
Bexarotene—Pain—Epirubicin—uterine cancer	0.000116	0.000265	CcSEcCtD
Bexarotene—Constipation—Epirubicin—uterine cancer	0.000116	0.000265	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000114	0.000261	CcSEcCtD
Bexarotene—RXRA—Gene Expression—PGR—uterine cancer	0.000114	0.000765	CbGpPWpGaD
Bexarotene—Insomnia—Doxorubicin—uterine cancer	0.000113	0.000259	CcSEcCtD
Bexarotene—Paraesthesia—Doxorubicin—uterine cancer	0.000113	0.000257	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	0.000112	0.000754	CbGpPWpGaD
Bexarotene—Dyspnoea—Doxorubicin—uterine cancer	0.000112	0.000255	CcSEcCtD
Bexarotene—Feeling abnormal—Epirubicin—uterine cancer	0.000112	0.000255	CcSEcCtD
Bexarotene—Somnolence—Doxorubicin—uterine cancer	0.000112	0.000255	CcSEcCtD
Bexarotene—Gastrointestinal pain—Epirubicin—uterine cancer	0.000111	0.000253	CcSEcCtD
Bexarotene—Dyspepsia—Doxorubicin—uterine cancer	0.00011	0.000252	CcSEcCtD
Bexarotene—Decreased appetite—Doxorubicin—uterine cancer	0.000109	0.000249	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	0.000109	0.00073	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—EZH2—uterine cancer	0.000108	0.000727	CbGpPWpGaD
Bexarotene—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000108	0.000247	CcSEcCtD
Bexarotene—Fatigue—Doxorubicin—uterine cancer	0.000108	0.000247	CcSEcCtD
Bexarotene—Pain—Doxorubicin—uterine cancer	0.000107	0.000245	CcSEcCtD
Bexarotene—Constipation—Doxorubicin—uterine cancer	0.000107	0.000245	CcSEcCtD
Bexarotene—Body temperature increased—Epirubicin—uterine cancer	0.000107	0.000245	CcSEcCtD
Bexarotene—Abdominal pain—Epirubicin—uterine cancer	0.000107	0.000245	CcSEcCtD
Bexarotene—RXRA—Metabolism—RRM2—uterine cancer	0.000105	0.000707	CbGpPWpGaD
Bexarotene—Feeling abnormal—Doxorubicin—uterine cancer	0.000103	0.000236	CcSEcCtD
Bexarotene—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000103	0.000234	CcSEcCtD
Bexarotene—RXRA—Metabolism—DCN—uterine cancer	0.000102	0.000686	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	0.000102	0.000685	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	0.000101	0.000675	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—ESR2—uterine cancer	0.0001	0.000674	CbGpPWpGaD
Bexarotene—Hypersensitivity—Epirubicin—uterine cancer	9.99e-05	0.000228	CcSEcCtD
Bexarotene—Abdominal pain—Doxorubicin—uterine cancer	9.92e-05	0.000226	CcSEcCtD
Bexarotene—Body temperature increased—Doxorubicin—uterine cancer	9.92e-05	0.000226	CcSEcCtD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	9.91e-05	0.000665	CbGpPWpGaD
Bexarotene—Asthenia—Epirubicin—uterine cancer	9.73e-05	0.000222	CcSEcCtD
Bexarotene—RXRA—Metabolism—CYP11A1—uterine cancer	9.64e-05	0.000647	CbGpPWpGaD
Bexarotene—Pruritus—Epirubicin—uterine cancer	9.59e-05	0.000219	CcSEcCtD
Bexarotene—Diarrhoea—Epirubicin—uterine cancer	9.28e-05	0.000212	CcSEcCtD
Bexarotene—Hypersensitivity—Doxorubicin—uterine cancer	9.24e-05	0.000211	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	9.18e-05	0.000616	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—AKR1C3—uterine cancer	9.1e-05	0.000611	CbGpPWpGaD
Bexarotene—Asthenia—Doxorubicin—uterine cancer	9e-05	0.000205	CcSEcCtD
Bexarotene—Dizziness—Epirubicin—uterine cancer	8.97e-05	0.000205	CcSEcCtD
Bexarotene—Pruritus—Doxorubicin—uterine cancer	8.88e-05	0.000203	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—ERBB2—uterine cancer	8.74e-05	0.000586	CbGpPWpGaD
Bexarotene—Vomiting—Epirubicin—uterine cancer	8.62e-05	0.000197	CcSEcCtD
Bexarotene—Diarrhoea—Doxorubicin—uterine cancer	8.58e-05	0.000196	CcSEcCtD
Bexarotene—Rash—Epirubicin—uterine cancer	8.55e-05	0.000195	CcSEcCtD
Bexarotene—Dermatitis—Epirubicin—uterine cancer	8.54e-05	0.000195	CcSEcCtD
Bexarotene—Headache—Epirubicin—uterine cancer	8.49e-05	0.000194	CcSEcCtD
Bexarotene—CYP2C9—Metabolism—SRD5A2—uterine cancer	8.32e-05	0.000558	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—NDUFB11—uterine cancer	8.32e-05	0.000558	CbGpPWpGaD
Bexarotene—Dizziness—Doxorubicin—uterine cancer	8.3e-05	0.000189	CcSEcCtD
Bexarotene—RXRA—Gene Expression—CDKN2B—uterine cancer	8.17e-05	0.000548	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	8.08e-05	0.000542	CbGpPWpGaD
Bexarotene—Nausea—Epirubicin—uterine cancer	8.05e-05	0.000184	CcSEcCtD
Bexarotene—Vomiting—Doxorubicin—uterine cancer	7.98e-05	0.000182	CcSEcCtD
Bexarotene—Rash—Doxorubicin—uterine cancer	7.91e-05	0.000181	CcSEcCtD
Bexarotene—Dermatitis—Doxorubicin—uterine cancer	7.9e-05	0.00018	CcSEcCtD
Bexarotene—Headache—Doxorubicin—uterine cancer	7.86e-05	0.000179	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—CTNNB1—uterine cancer	7.64e-05	0.000513	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	7.63e-05	0.000512	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—SMAD3—uterine cancer	7.46e-05	0.000501	CbGpPWpGaD
Bexarotene—Nausea—Doxorubicin—uterine cancer	7.45e-05	0.00017	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—EP300—uterine cancer	7.11e-05	0.000477	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—STK11—uterine cancer	7.09e-05	0.000476	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CYP19A1—uterine cancer	7.09e-05	0.000476	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—VEGFA—uterine cancer	6.73e-05	0.000452	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	6.65e-05	0.000447	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—NRAS—uterine cancer	6.65e-05	0.000446	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—EP300—uterine cancer	6.35e-05	0.000426	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—ESR1—uterine cancer	6.09e-05	0.000409	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—STAR—uterine cancer	6.01e-05	0.000403	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—AKR1B1—uterine cancer	6.01e-05	0.000403	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	5.94e-05	0.000399	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—KRAS—uterine cancer	5.72e-05	0.000384	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—SRD5A2—uterine cancer	5.48e-05	0.000368	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—NDUFB11—uterine cancer	5.48e-05	0.000368	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—MTHFR—uterine cancer	5.33e-05	0.000357	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—HRAS—uterine cancer	4.86e-05	0.000326	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—POLD1—uterine cancer	4.72e-05	0.000317	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.69e-05	0.000315	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—AKT1—uterine cancer	4.48e-05	0.000301	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—AKR1C1—uterine cancer	4.41e-05	0.000296	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—AKT1—uterine cancer	4.29e-05	0.000288	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—AKT1—uterine cancer	4.21e-05	0.000283	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—STAR—uterine cancer	3.97e-05	0.000266	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—AKR1B1—uterine cancer	3.97e-05	0.000266	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—RRM2—uterine cancer	3.93e-05	0.000264	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—DCN—uterine cancer	3.82e-05	0.000256	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CYP11A1—uterine cancer	3.6e-05	0.000241	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—AKR1C3—uterine cancer	3.4e-05	0.000228	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—POLD1—uterine cancer	3.11e-05	0.000209	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PTEN—uterine cancer	2.96e-05	0.000199	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—AKR1C1—uterine cancer	2.91e-05	0.000195	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—EP300—uterine cancer	2.83e-05	0.00019	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—STK11—uterine cancer	2.65e-05	0.000178	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CYP19A1—uterine cancer	2.65e-05	0.000178	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—RRM2—uterine cancer	2.59e-05	0.000174	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—DCN—uterine cancer	2.52e-05	0.000169	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.48e-05	0.000167	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CYP11A1—uterine cancer	2.37e-05	0.000159	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.37e-05	0.000159	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—AKR1C3—uterine cancer	2.24e-05	0.00015	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—AKT1—uterine cancer	2.2e-05	0.000147	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PIK3CA—uterine cancer	2.09e-05	0.00014	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—MTHFR—uterine cancer	1.99e-05	0.000133	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.75e-05	0.000118	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CYP19A1—uterine cancer	1.75e-05	0.000117	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—STK11—uterine cancer	1.75e-05	0.000117	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—AKT1—uterine cancer	1.71e-05	0.000115	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—MTHFR—uterine cancer	1.31e-05	8.8e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PTEN—uterine cancer	1.11e-05	7.42e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—EP300—uterine cancer	1.06e-05	7.08e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PIK3CA—uterine cancer	7.81e-06	5.24e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PTEN—uterine cancer	7.3e-06	4.9e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—EP300—uterine cancer	6.96e-06	4.67e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—AKT1—uterine cancer	6.38e-06	4.28e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PIK3CA—uterine cancer	5.15e-06	3.45e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—AKT1—uterine cancer	4.21e-06	2.82e-05	CbGpPWpGaD
